Lancet Respir Med: Polyglycol interferon treatment accelerates the removal of new coronavirus

To date, only monoclonal antibodies have been shown to be effective in outpatient patients with neo-coronary pneumonia.
interferon- 1 is a type III interferon that participates in congenitic antiviral reactions and has the activity of anti-respiratory pathogens.
study aims to assess the safety and effectiveness of polyethyl glycol interferon in the treatment of patients with mild to moderate neocyster pneumonia.
This is a double-blind, placebo-controlled clinical trial that recruits newly diagnosed patients with coronary pneumonia who are randomly assigned to the experimental group (180 μg of polyglycol interferon in a single subsurfed injection) or placebo group within one week of developing symptoms or asymptomatic but positive for pharynx swabs.
end of the disease is the proportion of patients with new coronavirus (SARS-CoV-2) RNA negative on the 7th day after injection.
between May 18 and September 4, 2020, 30 patients were recruited in each group.
Starting on the third day, the SARS-CoV-2 RNA drop in patients treated with polyethyl glycol interferon was greater than in the placebo group, and on the seventh day, there was a 2.42 log copy/ml gap between the two groups (p-0.0041).
Day 7 of the
, the viral load of 24 (80%) subjects in the polyethyl glycol interferon group was non-detectable, while the viral load of only 19 (63%) subjects in the placebo group was reduced to below detection (p-0.15).
After the baseline virus load was calibrated on day 7 of the virus removal probability calibration, the viral load of patients in the polyglycol interferon group at day 7 was more likely to be reduced to undetectable than in the placebo group (advantage ratio to the patients in the placebo group 4.12 (95% CI1.15-16.73; p=0.029) ).
in patients with a baseline viral load of more than 106 copies/mL, 15 (79%) of the 19 patients in the polyethyl glycol interferon group did not detect the virus on the 7th day, while 16 patients in the placebo group Six (38%) did not detect the virus on the 7th day (OR 6.25 (95% CI 1.49-31.06) ;p x 0.012).
Polyethyl glycol interferon is well-to-resistant, adverse reactions between the two groups are similar, adverse reactions between groups using mild and transient amino transferases are similar, and elevated concentrations of mild transaminase are more common in the polyethyl glycol interferon group.
two groups each reached the level 3 elevation threshold, and no other level 3-4 adverse reactions were reported.
, polyglycol interferon therapy has accelerated the reduction of viral load in outpatients with neo-coronary pneumonia, increasing the proportion of patients who have been cleared of the virus on the 7th day, especially those with higher baseline viral loads.
glycol interferon has the potential to prevent clinical deterioration and shorten the duration of virus shedding.